Results 11 to 20 of about 11,456 (188)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation [PDF]

Frontiers in Pharmacology, 2019
Recent clinical trials revealed that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce cardiovascular events in type 2 diabetic patients, however, canagliflozin increased limb amputations, an effect not seen with other SGLT2 ...
Ghazaleh Behnammanesh, Zane E. Durante, Kelly J. Peyton, Luis A. Martinez-Lemus, Luis A. Martinez-Lemus, Scott M. Brown, Scott M. Brown, Shawn B. Bender, Shawn B. Bender, Shawn B. Bender, William Durante   +10 more
doaj   +2 more sources

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice

Drug Design, Development and Therapy, 2022
Qingjuan Zuo,1,2 Guorui Zhang,1,3 Lili He,2 Sai Ma,4 Huijuan Ma,5 Jianlong Zhai,6 Zhongli Wang,7 Tingting Zhang,2 Yan Wang,2 Yifang Guo1,2 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department ...
Zuo Q, Zhang G, He L, Ma S, Ma H, Zhai J, Wang Z, Zhang T, Wang Y, Guo Y   +9 more
doaj   +1 more source

Canagliflozin and Cardiovascular disease- results of the CANVAS trial

Journal of Community Hospital Internal Medicine Perspectives, 2018
Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium–glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to ...
Syed Raza Shah, Najla Issa Najim, Zainab Abbasi, Mazia Fatima, Ayesha Altaf Jangda, Waqas Shahnawaz, Maira Shahid, Syed Arbab Shah   +7 more
doaj   +2 more sources

Canagliflozin review – safety and efficacy profile in patients with T2DM

Diabetes, Metabolic Syndrome and Obesity, 2019
Haroon Jakher,1 Tara I Chang,2 Marilyn Tan,3 Kenneth W Mahaffey4 1Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; 2Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA ...
Jakher H, Chang TI, Tan M, Mahaffey KW
doaj   +1 more source

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination

Diabetes, Metabolic Syndrome and Obesity, 2015
Joshua W Fleming, Laurie W Fleming, Courtney S Davis Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA Abstract: Canagliflozin–metformin is one of the newest combination therapies available for the
Fleming JW, Fleming LW, Davis CS
doaj   +1 more source

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes

International Journal of General Medicine, 2017
Susan C Bolge,1 Natalia M Flores,2 Shu Huang,3 Jennifer Cai1 1Janssen Scientific Affairs, LLC, Titusville, NJ, 2Kantar Health, Foster City, CA, 3Kantar Health, New York, NY, USA Purpose: This study describes how health care providers approach ...
Bolge SC, Flores NM, Huang S, Cai J
doaj   +1 more source

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Diabetes, Metabolic Syndrome and Obesity, 2017
Michael J Davies,1 Katherine W Merton,1 Ujjwala Vijapurkar,2 Dainius A Balis,2 Mehul Desai2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, LLC, Raritan, NJ, USA Objective: Metabolic syndrome refers to a ...
Davies MJ, Merton KW, Vijapurkar U, Balis DA, Desai M   +4 more
doaj   +1 more source

The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review [PDF]

Current Internal Medicine Research and Practice Surabaya Journal
Introduction: One of the leading causes of death in patients with diabetes mellitus is Diabetic Kidney Disease (DKD). Canagliflozin is one of the therapeutic options that can be used to mitigate the progression of DKD.
Vikri Haikal, Soebagijo Adi Soelistijo, Puspa, Jongky Hendro Prajitno   +3 more
doaj   +2 more sources

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program [PDF]

, 2021
Background: The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to reduce the risk of cardiovascular and renal events in patients with Type 2 diabetes mellitus and high risk.
Weir, Matthew R, Perkovic, Vlado, Slee, April, Balis, Dainius, Sun, Tao, de Zeeuw, Dick; id_orcid, Oh, Richard, de Zeeuw, Dick   +7 more
core   +2 more sources

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus. [PDF]

Br J Clin Pharmacol
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Goeyvaerts N, Gisleskog PO, Neyens M, Ruixo JJP, Ali SR, Cirillo I, Ackaert O.   +6 more
europepmc   +2 more sources